NCT05068674View on ClinicalTrials.gov

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions
Chronic Ischemic Left Ventricular Dysfunction
Interventions
DRUG

Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells

50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.

DRUG

Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells

150M cells delivered in a dose of 15M cells per injection over 10 injections

DRUG

Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells

300M cells delivered in a dose of 30M per injection over 10 injections

Trial Locations (1)

94305

RECRUITING

Stanford Hospital and Clinics, Palo Alto

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Joseph C. Wu

OTHER